Skip to main content
October 6, 2016
Public Policy Priority Health IT Standards & Interoperability
Statement Type Regulatory Comment

In comments submitted to the FDA, AMIA said it supports FDA’s efforts to develop modern, flexible and adaptive regulatory approaches to the oversight of NGS-based tests as part of the Precision Medicine Initiative (PMI).  This support notwithstanding, AMIA noted a lack of standards – for ontologies, metadata and other technical aspects of using human genetic variant databases for NGS-based diagnostics.